Home  »  Industry   »  Vertex Pharmaceuticals Incorporated (VRTX) Stock C...

Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Soon Reward Patient Investors

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is 7.97% higher on its value in year-to-date trading and has touched a low of $221.69 and a high of $324.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $309.84 in the last trading session, with the day’s gains setting it 1.97% off its average median price target of $327.00 for the next 12 months. It is also 29.13% off the consensus price target high of $440.00 offered by 30 analysts, but current levels are -11.36% lower than the price target low of $280.00 for the same period.

Currently trading at $311.81, the stock is 6.11% and 2.45% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.81 million and changing 0.64% at the moment leaves the stock 8.41% off its SMA200. VRTX registered 36.39% gain for a year compared to 6-month gain of 11.25%.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The stock witnessed a 6.34% loss in the last 1 month and extending the period to 3 months gives it a 7.46%, and is 3.61% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.18% over the week and 2.12% over the month.

Vertex Pharmaceuticals Incorporated (VRTX) has around 3900 employees, a market worth around $79.55B and $8.70B in sales. Current P/E ratio is 24.61 and Fwd P/E is 19.73. Profit margin for the company is 37.60%. Distance from 52-week low is 40.65% and -3.98% from its 52-week high. The company has generated returns on investments over the last 12 months (22.50%).

Vertex Pharmaceuticals Incorporated (VRTX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Vertex Pharmaceuticals Incorporated (VRTX) is a “Overweight”. 30 analysts offering their recommendations for the stock have an average rating of 2.20, where 11 rate it as a Hold and 3 think it is a “Overweight”. 16 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Vertex Pharmaceuticals Incorporated is expected to release its quarterly report on 05/03/2023.The EPS is expected to shrink by -12.50% this year.

Vertex Pharmaceuticals Incorporated (VRTX) Top Institutional Holders

The shares outstanding are 256.50M, and float is at 256.21M with Short Float at 0.98%.

Vertex Pharmaceuticals Incorporated (VRTX) Insider Activity

A total of 73 insider transactions have happened at Vertex Pharmaceuticals Incorporated (VRTX) in the last six months, with sales accounting for 65 and purchases happening 8 times. The most recent transaction is an insider sale by Lee Yuchun,the company’sDirector. SEC filings show that Lee Yuchun sold 442 shares of the company’s common stock on Jan 18 at a price of $312.17 per share for a total of $0.14 million. Following the sale, the insider now owns 1875.0 shares.

Vertex Pharmaceuticals Incorporated disclosed in a document filed with the SEC on Jan 17 that Lee Yuchun (Director) sold a total of 4,000 shares of the company’s common stock. The trade occurred on Jan 17 and was made at $312.03 per share for $1.25 million. Following the transaction, the insider now directly holds 1875.0 shares of the VRTX stock.

Still, SEC filings show that on Nov 15, ALTSHULER DAVID (EVP, Global Research and CSO) disposed off 34 shares at an average price of $308.61 for $10493.0. The insider now directly holds 36,077 shares of Vertex Pharmaceuticals Incorporated (VRTX).

Vertex Pharmaceuticals Incorporated (VRTX): Who are the competitors?

The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading 11.67% up over the past 12 months and Krystal Biotech Inc. (KRYS) that is 42.18% higher over the same period. Arcturus Therapeutics Holdings Inc. (ARCT) is -25.40% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts